Intervacc: Getting back in the saddle - Redeye

Redeye initiates coverage of Intervacc, a veterinary vaccine company focused on infectious diseases in horses. Following a slower-than-expected commercial rollout and a series of equity issues, the share price has fallen significantly from previous highs. We believe the market underestimates the long-term sales potential of Strangvac, particularly in the US.

Länk till analysen i sin helhet: https://www.redeye.se/research/1171044/intervacc-getting-back-in-the-saddle?utm_source=finwire&utm_medium=RSS